A clinical trial for drug fosigotifator in ALS patients failed to meet its primary endpoint, with no marked effect on disease progression, according to results from the Healey ALS platform trial. Produced by Calico Life Sciences with AbbVie, it showed no significant improvement in secondary endpoints either. However, slower deterioration in muscle strength was observed. Fosigotifator continues to be studied for other diseases.
AI-powered malware could breach security systems in seconds: NATO-backed start-up
Kines warned that AI-powered security tools alone cannot counter AI-driven malware. A multi-layered defense strategy, blending AI-enhanced detection systems with network segmentation tools, is necessary.
